Navigation Links
Tackling Atrial Fibrillation and Associated Cardiovascular Risk
Date:11/4/2008

- RecordAF Registry Baseline Data and New Data from the Landmark ATHENA

Study
PARIS, Nov. 4 /PRNewswire/ --

Live Webcast Media Briefing - non-US media only

Wednesday 12 November 2008 - 14.00-15.00am CET

Background:

-- AF is a growing health concern directly responsible for increased

morbidity and mortality

-- There is a need for a global prospective database like RecordAF, which

takes a closer look at disease characteristics and how management of AF

affects cardiovascular (CV) outcomes

-- AF is associated with a high hospitalization burden - 70 percent of AF

management costs are driven by hospitalization costs (Ringborg et al.

Europace 2008; 10:403-11)

-- A further sub-analysis of the ATHENA trial was conducted:

-- to better understand the impact of dronedarone on hospitalization

of AF patients particularly on the number and duration of CV and

non CV hospitalization nights

-- An additional sub-analysis was also conducted to further explore

dronedarone's rhythm and rate controlling properties

-- The ATHENA study is the first AF trial designed to evaluate the effect

of an anti arrhythmic drug (AAD) on morbidity and mortality. It showed

that dronedarone (brand name Multaq(R)), a new AAD undergoing the

registration process, can significantly improve CV outcomes including

reducing the risk of hospitalization and death.

Register on-line in advance of the online event:

1. Go to https://sanofiaventismediabriefing.webex.com/sanofiaventismediabriefing/ons t age/g.php?d=702842657&t=a&EA=nburns%40webex.com&ET=6b1f2c181b8fa5176928ed1c 72 009c4d&ETR=8789fb6f20765cb360e4d0c88cea0f23 (due to the length of this URL, please copy a
'/>"/>

SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
2. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
3. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
4. Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
7. Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
8. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
9. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
10. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
11. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LONDON , September 18, 2014 ... their audience, has updated the incredibly successful Serialisation Countdown ... The interactive PDF, available at pharmaserialisation.com shows ... in which they will be coming into force. ... no longer a matter of "if", but "when" they ...
(Date:9/18/2014)... , Sept. 18, 2014  Zacks.com announces the list ... the Zacks Equity Research analysts discuss the latest news ... recently featured in the blog include the Avanir Pharmaceuticals (Nasdaq: ... NPSP - Free Report ), Orexigen (Nasdaq: ... - Free Report ) and Gilead (Nasdaq: GILD ...
(Date:9/18/2014)... , Sept. 18, 2014  Neurotrope, Inc. (OTCQB: NTRP) ... , M.D., Ph.D. to the Company,s Board of Directors, ... fills a vacancy on the Board of seven members. ... and Corporate Governance Committee and a member of the ... a member of Neurotrope,s Scientific Advisory Board, a position ...
Breaking Medicine Technology:Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4
... AGAWAM, Mass., June 7, 2011 A free white ... validation of their cleaning processes is available from Microtest ... . As many medical devices are made ... plastics, manufacturers may require the use of various agents ...
... Biomedical Inc., a developer of an advanced implantable vena cava ...  The round was led by Three Arch Partners, which was ... Vena cava filters, which were first introduced ... that can lead to a potentially fatal pulmonary embolism (PE). ...
Cached Medicine Technology:New White Paper Helps Medical Device Manufacturers Validate Cleaning Processes 2Crux Successfully Completes Funding for Advanced Filter for PE Prevention 2
(Date:9/18/2014)... PA (PRWEB) September 18, 2014 "Medical ... patient care while also maintaining the patient's privacy," said ... up with this idea in order to supply caregivers ... well." , They created a prototype for The Helper ... device enables staff to turn patient onto his or ...
(Date:9/18/2014)... 2014 Companies in the Carbon ... selling it to downstream industries in either gas, liquid ... are food and beverage manufacturers. Food producers use carbon ... or pizzas. The gas is also used as a ... to carbonate soft drinks, beer and other beverages. According ...
(Date:9/18/2014)... Daily supplements of selenium or vitamin E don,t seem ... among men, a new study indicates. Previous animal ... prevent cataracts. To investigate this further, William Christen, from ... Boston, and his colleagues examined data from a randomized, ... was initially designed to study prevention of prostate cancer. ...
(Date:9/18/2014)... Lambertville, NJ (PRWEB) September 18, 2014 ... consulting firm, announced today that President and co-founder ... Business Journal’s Innovation Award Winners for 2014, recognizing ... naming him as an emerging executive of the ... health care and life sciences that continue to ...
(Date:9/18/2014)... 18, 2014 Stealth Health Revolution ... advocate, and Frank Davis, founder of Food for ... are pleased to announce the new recipe book, ... delicious, nutrition-packed meals using Activz whole-food powders." ... step in the Stealth Health Revolution ...
Breaking Medicine News(10 mins):Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3
... ... scores to the Centers for Medicare and Medicaid Services , ... Houston, TX (PRWEB) October 6, 2009 -- ... beneficiaries in the counties of Harris, Fort Bend, Montgomery, and Galveston on the Mainland, ...
... , New National Survey Finds Jobless Individuals Four Times ... 6 A new national survey shows the economic downturn is ... who are unemployed are four times as likely as those with ... Americans who experienced involuntary changes in their employment status, such as ...
... Oct. 6 iJET Intelligent Risk Systems, a ... services, today announced the third webinar in its ... Resiliency." These interactive webinars help multinational organizations institute ... their organizations, especially amidst the ongoing effects of ...
... ... gathered recently at the Massachusetts Institute of Technology,s Faculty Club for ... being used to save lives, reduce suffering and extend human potential. ... by Alexander Medvedev, PhD., Vice President, Research & Development, Terumo Heart, ...
... bioTheranostics, a bioMerieux company that discovers, develops and commercializes ... company has signed a two-year agreement with Lab21 to ... in the United Kingdom (UK), Ireland and Middle East ... the terms of the agreement, UK-based Lab21 will market ...
... ... the parts washing industry. Midbrook has extensive experience washing parts and equipment in a variety ... facility to help a North American automotive parts supplier solve a de-rusting issue. , ... (Vocus) October 6, 2009 -- ...
Cached Medicine News:Health News:Local Medicare Advantage Plan Scores High on Diabetic Care and Blood Pressure Control 2Health News:Economic Downturn Taking Toll on Americans' Mental Health 2Health News:Economic Downturn Taking Toll on Americans' Mental Health 3Health News:iJET's 'Survive/Thrive' Webinar Series Continues With 'Pandemic Influenza: Where Do We Stand?' 2Health News:iJET's 'Survive/Thrive' Webinar Series Continues With 'Pandemic Influenza: Where Do We Stand?' 3Health News:Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit 2Health News:Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit 3Health News:bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries 2Health News:bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries 3Health News:Midbrook Production Washing A Valuable Partner 2Health News:Midbrook Production Washing A Valuable Partner 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: